Wolfgang Trefzger

Heidelberg Innovation Fonds Management GmbH (Heidelberg Innovation) is an independent German venture capital firm which was founded in 1997 by Dr. Ulrich Abshagen. In addition to providing financial capital, Heidelberg Innovation's 'network and knowledge capital', in the form of entrepreneurial experience, technical expertise and their network of experts and contacts, is a decisive added value for their investee companies. Based in Leimen, the firm manages the Heidelberg Innovation BioScience Venture II, Heidelberg Innovation Parallel Participation and the Heidelberg Innovation BioScience Venture I funds for investors including the European Investment Fund, insurance companies, banks, fund-of-fund investors and private individuals.

Digilab BioVisioN GmbH provides research services in the area of peptide analysis to health care by discovering and developing novel substances and methods to diagnose and treat human diseases. Its partners include Roche Diagnostics GmbH for the discovery of novel biomarker candidates of Alzheimer's disease and Novo Nordisk for the search for novel therapeutic approaches in type 2 diabetes. The company was founded in 1997 and is headquartered in Hannover, Germany.